WASHINGTON — President Trump is back in attack mode — and drug companies are again a clear target.

In a rowdy, hourlong speech at a sprawling Florida retirement home, Trump renewed his pointed criticisms of the pharmaceutical industry, even implying they may have been behind the recent push to open a formal impeachment investigation.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • I guess Mr Trump has a short memory. This past May he made a speech in the Rose garden of the White House
    pointing out that the PBM’s were making billions of dollars and he was going to put a stop to it!!
    If President Trump wants to lower drug prices he MUST stop the PBM’s from fleecing every american in this
    country! Alex Azar was the CEO of Eli Lilly, he was the one paying these “Drug Rebates”, which by the way is
    really EXTORTION money. He knows better than anyone who the thieves are in this drug game. The PBM’s are!
    It’s so simple !!!!

Comments are closed.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy